세계의 일회용 바이오리액터 시장 : 제품별, 유형별, 분자 유형별, 세포 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2029년)

The global single-use bioreactors market is projected to reach USD 9.1 billion by 2029 from USD 4.4 billion in 2024, at a CAGR of 15.4% during the forecast period of 2024 to 2029. The advantages of SUBs above conventional bioreactors drive the market expansion. Made of premium plastic materials, SUBs are intended for single-use use hence sterilizing and cleaning between batches is not necessary. This lowers cross-contamination risk greatly and increases operational effectiveness. The rise of SUBs as a fundamental technology inside the single-use bioprocessing sector has transformed the development and manufacturing of biopharmaceutical products. Their benefits over traditional stainless-steel bioreactors make them the preferred option for biopharmaceutical companies, CMOs, and research facilities.

"The pharmaceutical & biotechnology companies segment accounted for the largest share by end user in 2023."

In 2023, the pharmaceutical & biotechnology companies segment accounted for the largest share by end user in the global single-use bioreactors market. The growth in this market can be attributed to rising R&D initiatives by pharmaceutical, biopharmaceutical, and biotechnology companies and the increased production of biologics and biosimilars. Moreover, the widespread use of SUBs among pharmaceutical and biotechnology companies across established and developed markets, such as North America and Europe, and the rising approvals of biologics and biosimilars in these regions are the major factors supporting the growth of this end-user segment.

"The US has continued to dominate the single-use bioreactors market during the forecast period of 2024-2029."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Pharmaceutical companies in the US are actively participating in developing biologics and biosimilars and increasingly utilizing single-use bioreactors, which offers less turnaround time, has low installation costs, and is energy-efficient. These factors support the growth of the US single-use bioreactors market. Furthermore, the expiry of many biologics contributes to the growth of the biopharmaceutical industry in the US. The US accounts for the highest number of patents due for expiration. Several strategies are being undertaken by pharmaceutical companies in the US, such as the development of biosimilars, new formulations for patented drugs, new routes of administration for known drugs, and combinations for extending drug commercial lifecycles, which will result in an increase in biopharmaceutical R&D and new generations of biologic medicines. As single-use bioreactors are associated with a low risk of contamination and low implementation costs, their adoption in biopharmaceutical companies for R&D is expected to increase. These factors are supporting the growth of the single-use bioreactors market in the country.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Sartorius AG (Germany)

Danaher Corporation (US)

Thermo Fisher Scientific Inc. (US)

Merck KGaA (Germany)

Avantor, Inc. (US)

Repligen Corporation (US)

Getinge AB (Sweden)

Eppendorf SE (Germany)

Parker Hannifin Corporation (US)

Entegris (US)

Saint-Gobain (France)

Corning Incorporated (US)

Lonza (Switzerland)

TECNIC Bioprocess Equipment Manufacturing (Spain)

FUJIMORI KOGYO CO., LTD. (Japan)

Kuhner AG (Switzerland)

OmniBRx Biotechnologies (India)

New Horizon Biotechnology, Inc. (US)

PBS Biotech, Inc. (US)

bbi-biotech GmbH (Germany)

ABEC, Inc. (US)

Esco Lifesciences Group Ltd. (US)

Distek, Inc. (US)

SATAKE MultiMix Corporation (Japan)

Cell Culture Company, LLC (US)

Micro Digital Co., Ltd. (South Korea)

Celltainer Biotech B.V. (Netherlands)

Meissner Filtration Products, Inc. (US)

Solida Biotech GmbH (Germany)

G&G Technologies, Inc. (US)

PharmNXT Biotech (India)

Tofflon Life Science Co., Ltd. (China)

Research Coverage:

This research report categorizes the single-use bioreactors market by product (single-use bioreactor systems, single-use media bags, single-use assemblies, and other products), by type (stirred-tank single-use bioreactors, wave-induced single-use bioreactors, bubble-column single-use bioreactors, and other single-use bioreactors), by molecule type (monoclonal antibodies (mAbs), vaccines, therapeutic proteins & peptides, stem cells, and cell & gene therapy), by cell type (mammalian cells, bacterial cells, yeast cells, and other cells), by application (bioproduction, process development, and research & development (R&D)), by end user (pharmaceutical & biotechnology companies, contract research organizations & contract manufacturing organizations (CROs & CMOs), and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the single-use bioreactors market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the single-use bioreactors market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall single-use bioreactors market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing adoption among CDMOs, CMOs, and SMEs, advantages over conventional bioreactors, reduced capital investment, reduced water and energy consumption, growing biologics & biosimilars markets), restraints (issues related to extractables & leachables, regulatory hurdles and compliance issues, and, the impact of PFAS restrictions on product development), opportunities (untapped market potential in emerging economies and hybrid facilities), and Challenges (lack of standardization, waste disposal, and potential breakage of SU bags) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the single-use bioreactors market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-use bioreactors market
• Competitive Assessment: Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), Repligen Corporation (US), Entegris (US), Getinge AB (Sweden), Parker Hannifin Corporation (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS
• 2.8 GENERATIVE AI IMPACT ON SINGLE-USE BIOREACTORS MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SINGLE-USE BIOREACTORS MARKET OVERVIEW
• 4.2 NORTH AMERICA: SINGLE-USE BIOREACTORS MARKET, BY APPLICATION AND COUNTRY (2023)
• 4.3 SINGLE-USE BIOREACTORS MARKET, BY END USER, 2024 VS. 2029
• 4.4 SINGLE-USE BIOREACTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing adoption among CDMOs, CMOs, and SMEs
    • 5.2.1.2 Advantages over conventional bioreactors
    • 5.2.1.3 Reduced capital investment
    • 5.2.1.4 Reduced water and energy consumption
    • 5.2.1.5 Growing biologics & biosimilars markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Issues related to extractables & leachables
    • 5.2.2.2 Regulatory hurdles and compliance issues
    • 5.2.2.3 Impact of PFAS restrictions on product development
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Untapped market potential in emerging economies
    • 5.2.3.2 Hybrid facilities
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of standardization
    • 5.2.4.2 Waste disposal
    • 5.2.4.3 Potential breakage of SU bags
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER, 2023
  • 5.4.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION, 2023
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 SINGLE-USE BIOREACTORS MARKET: RAW MATERIAL SUPPLIERS
  • 5.7.2 SINGLE-USE BIOREACTORS MARKET: MANUFACTURERS
  • 5.7.3 SINGLE-USE BIOREACTORS MARKET: END USERS
  • 5.7.4 SINGLE-USE BIOREACTORS MARKET: REGULATORY BODIES
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Fermentation
    • 5.8.1.2 Continuous bioprocessing
    • 5.8.1.3 3D cell culture
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
  • 5.8.3 ADJACENT TECHNOLOGIES
• 5.9 PATENT ANALYSIS
• 5.10 KEY CONFERENCES AND EVENTS IN 2024-2025
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY SCENARIO
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
      • 5.11.1.2.1 Germany
      • 5.11.1.2.2 UK
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 Japan
      • 5.11.1.3.2 China
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 INVESTMENT & FUNDING SCENARIO
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA FOR END USERS
• 5.15 TRADE ANALYSIS
• 5.16 IMPACT OF GENERATIVE AI ON SINGLE-USE BIOREACTORS MARKET

6 SINGLE-USE BIOREACTORS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SINGLE-USE BIOREACTOR SYSTEMS
  • 6.2.1 <=10 L BIOREACTORS
    • 6.2.1.1 Flexibility in early-stage R&D to boost market
  • 6.2.2 11-100 L BIOREACTORS
    • 6.2.2.1 Scalability for process development to drive demand
  • 6.2.3 101-500 L BIOREACTORS
    • 6.2.3.1 Efficiency in pilot-scale production to propel demand
  • 6.2.4 501-1500 L BIOREACTORS
    • 6.2.4.1 Growing use in large-scale commercial production to drive market
  • 6.2.5 >1500 L BIOREACTORS
    • 6.2.5.1 Rising adoption of single-use technologies in high-demand applications to support market growth
• 6.3 SINGLE-USE MEDIA BAGS
  • 6.3.1 2D SINGLE-USE MEDIA BAGS
    • 6.3.1.1 Wide use of 2D bags in cell culture applications to drive market growth
  • 6.3.2 3D SINGLE-USE MEDIA BAGS
    • 6.3.2.1 Usage in large-volume applications to drive market growth
  • 6.3.3 OTHER SINGLE-USE MEDIA BAGS
• 6.4 SINGLE-USE ASSEMBLIES
  • 6.4.1 OPERATIONAL EFFICIENCY AND FLEXIBILITY TO PROPEL DEMAND FOR SINGLE-USE ASSEMBLIES
• 6.5 OTHER PRODUCTS

7 SINGLE-USE BIOREACTORS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 STIRRED-TANK SINGLE-USE BIOREACTORS
  • 7.2.1 GROWING PREFERENCE FOR AEROBIC MICROBIAL CELL CULTURES TO SUPPORT MARKET GROWTH
• 7.3 WAVE-INDUCED SINGLE-USE BIOREACTORS
  • 7.3.1 GROWING ADOPTION FOR SHEAR STRESS-SENSITIVE CELL LINES TO FUEL GROWTH
• 7.4 BUBBLE-COLUMN SINGLE-USE BIOREACTORS
  • 7.4.1 EFFICIENT MASS AND HEAT TRANSFER CAPABILITY TO DRIVE GROWTH
• 7.5 OTHER SINGLE-USE BIOREACTORS

8 SINGLE-USE BIOREACTORS MARKET, BY MOLECULE TYPE

• 8.1 INTRODUCTION
• 8.2 MONOCLONAL ANTIBODIES
  • 8.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO DRIVE DEMAND FOR SINGLE-USE BIOREACTORS
• 8.3 VACCINES
  • 8.3.1 USE OF SINGLE-USE SYSTEMS FOR VACCINE PRODUCTION TO BOOST MARKET GROWTH
• 8.4 THERAPEUTIC PROTEINS & PEPTIDES
  • 8.4.1 ABILITY OF SINGLE-USE TECHNOLOGIES TO HELP MINIMIZE CROSS-CONTAMINATION RISK TO BOOST ADOPTION
• 8.5 STEM CELLS
  • 8.5.1 GROWING RESEARCH AND COMMERCIALIZATION OF STEM CELL THERAPIES TO DRIVE MARKET
• 8.6 CELL & GENE THERAPY
  • 8.6.1 INCREASING RESEARCH INITIATIVES FOR GENE AND CELL THERAPIES TO DRIVE MARKET

9 SINGLE-USE BIOREACTORS MARKET, BY CELL TYPE

• 9.1 INTRODUCTION
• 9.2 MAMMALIAN CELLS
  • 9.2.1 GROWING USE OF MAMMALIAN CELLS IN PRODUCTION OF MONOCLONAL ANTIBODIES TO DRIVE MARKET
• 9.3 BACTERIAL CELLS
  • 9.3.1 GROWING ADOPTION IN COMMERCIAL VACCINES AND RECOMBINANT PROTEIN PRODUCTION TO DRIVE MARKET
• 9.4 YEAST CELLS
  • 9.4.1 HIGH GROWTH RATE AND MINIMAL MEDIA CONDITIONS TO DRIVE ADOPTION IN RECOMBINANT PROTEIN PRODUCTION
• 9.5 OTHER CELLS

10 SINGLE-USE BIOREACTORS MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 BIOPRODUCTION
  • 10.2.1 INCREASING BIOPHARMACEUTICAL PRODUCTION TO DRIVE DEMAND FOR COST-EFFECTIVE SINGLE-USE BIOREACTORS
• 10.3 PROCESS DEVELOPMENT
  • 10.3.1 ACCELERATED TIME-TO-MARKET TO PROPEL ADOPTION
• 10.4 RESEARCH & DEVELOPMENT
  • 10.4.1 RISING ADOPTION OF SINGLE-USE BIOREACTORS FOR COST-EFFECTIVENESS TO DRIVE MARKET

11 SINGLE-USE BIOREACTORS MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 GROWING BIOLOGICS AND BIOSIMILARS MARKET TO INCREASE DEMAND FOR SINGLE-USE BIOREACTORS
• 11.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
  • 11.3.1 INCREASING OUTSOURCING OF R&D AND MANUFACTURING TO SUPPORT MARKET GROWTH
• 11.4 ACADEMIC & RESEARCH INSTITUTES
  • 11.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL & BIOPHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO DRIVE MARKET

12 SINGLE-USE BIOREACTORS MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 US to dominate North American market during study period
  • 12.2.2 CANADA
    • 12.2.2.1 Increasing government support for biologics manufacturing and rising research funding to propel market growth
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 High government R&D investment and technological advancements to aid market growth
  • 12.3.2 UK
    • 12.3.2.1 Increased government funding for pharmaceutical & biotechnology research to boost market growth
  • 12.3.3 FRANCE
    • 12.3.3.1 Favorable government initiatives and increased investments by foreign pharmaceutical companies to augment market growth
  • 12.3.4 ITALY
    • 12.3.4.1 Increasing government grants for biopharmaceutical and life science research to support market
  • 12.3.5 SPAIN
    • 12.3.5.1 Rising focus on personalized medicine to fuel market growth
  • 12.3.6 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 CHINA
    • 12.4.1.1 Low manufacturing costs and high investments in biotechnology sector to spur market growth
  • 12.4.2 SOUTH KOREA
    • 12.4.2.1 Increased focus on quality manufacturing practices to aid market growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing collaborations among biotechnology companies to drive market
  • 12.4.4 INDIA
    • 12.4.4.1 High foreign direct investments and favorable government policies to propel market growth
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Increased demand for innovative research solutions and developed pharmaceutical industry to support market growth
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Increasing pharmaceutical R&D to fuel market growth
  • 12.5.2 MEXICO
    • 12.5.2.1 Increased foreign direct investment from US and reduced pharmaceutical manufacturing costs to boost market growth
  • 12.5.3 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 GCC COUNTRIES
    • 12.6.1.1 Saudi Arabia
      • 12.6.1.1.1 Rising healthcare expenditure to boost market growth
    • 12.6.1.2 UAE
      • 12.6.1.2.1 Increasing collaborations among biopharma companies to aid market growth
    • 12.6.1.3 Rest of GCC countries
  • 12.6.2 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 INCREASING DEMAND FOR DRUGS AND GROWING PATIENT POOL TO PROPEL MARKET GROWTH

13 COMPETITIVE LANDSCAPE

• 13.1 OVERVIEW
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN SINGLE-USE BIOREACTORS MARKET
• 13.3 REVENUE ANALYSIS
• 13.4 MARKET SHARE ANALYSIS
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Product footprint
    • 13.5.5.4 Application footprint
    • 13.5.5.5 End-user footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 SARTORIUS AG
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 DANAHER CORPORATION
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Deals
      • 14.1.2.3.2 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 THERMO FISHER SCIENTIFIC INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Deals
      • 14.1.3.3.2 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 MERCK KGAA
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Deals
      • 14.1.4.3.3 Expansions
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 AVANTOR, INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
      • 14.1.5.3.2 Expansions
  • 14.1.6 REPLIGEN CORPORATION
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
      • 14.1.6.3.2 Expansions
  • 14.1.7 GETINGE AB
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Expansions
  • 14.1.8 EPPENDORF SE
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
  • 14.1.9 PARKER HANNIFIN CORPORATION
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
  • 14.1.10 ENTEGRIS
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Expansions
  • 14.1.11 SAINT-GOBAIN
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
      • 14.1.11.3.2 Expansions
  • 14.1.12 CORNING INCORPORATED
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
  • 14.1.13 LONZA
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
  • 14.1.14 TECNIC BIOPROCESS EQUIPMENT MANUFACTURING
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches
      • 14.1.14.3.2 Deals
      • 14.1.14.3.3 Expansions
  • 14.1.15 FUJIMORI KOGYO CO., LTD.
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Expansions
• 14.2 OTHER PLAYERS
  • 14.2.1 KUHNER AG
  • 14.2.2 OMNIBRX BIOTECHNOLOGIES
  • 14.2.3 NEW HORIZON BIOTECHNOLOGY, INC.
  • 14.2.4 PBS BIOTECH, INC.
  • 14.2.5 BBI-BIOTECH GMBH
  • 14.2.6 ABEC, INC.
  • 14.2.7 ESCO LIFESCIENCES GROUP LTD.
  • 14.2.8 DISTEK, INC.
  • 14.2.9 SATAKE MULTIMIX CORPORATION
  • 14.2.10 CELL CULTURE COMPANY, LLC
  • 14.2.11 MICRO DIGITAL CO., LTD.
  • 14.2.12 CELLTAINER BIOTECH B.V.
  • 14.2.13 MEISSNER FILTRATION PRODUCTS, INC.
  • 14.2.14 SOLIDA BIOTECH GMBH
  • 14.2.15 G&G TECHNOLOGIES, INC.
  • 14.2.16 PHARMNXT BIOTECH
  • 14.2.17 TOFFLON LIFE SCIENCE CO., LTD.
  • 14.2.18 SHANGHAI LEPURE BIOTECH CO., LTD.

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS